In the Initial, Retreatment, and Monitoring sections, recommendations regarding the use of paritaprevir/ritonavir/ombitasvir plus dasabuvir in those with advanced liver disease have been revised based on an FDA warning issued on October 22, 2015.
In the Initial, Retreatment, and Monitoring sections, recommendations regarding the use of paritaprevir/ritonavir/ombitasvir plus dasabuvir in those with advanced liver disease have been revised based on an FDA warning issued on October 22, 2015.